Çѱ¹ÀüÅëÀÇÇבּ¸¼Ò ÀÚȸ»çÀÎ, ¿ì¼öÇѾàÀçÀ¯ÅëÁö¿ø... 2016
9.8
Çѱ¹ÀüÅëÀÇÇבּ¸¼Ò ÀÚȸ»çÀÎ, ¿ì¼öÇѾàÀçÀ¯ÅëÁö¿ø¼¾ÅÍ ¢ß¸Þ°¡¹ÙÀÌ¿À¡°¿ø¿ÜÅÁÀü °³¼³¡±   - Á¤Á¦, ĸ½¶...
¢ßÇѱ¹ÀüÅëÀÇÇבּ¸¼Ò, ³²¼ººÒÀÓÄ¡·áÁ¦ Èĺ¸¹°Áú ... 2016
9.6
¢ßÇѱ¹ÀüÅëÀÇÇבּ¸¼Ò, ³²¼ººÒÀÓÄ¡·áÁ¦ Èĺ¸¹°Áú KH-465,  ¡®ÀϹݾฮ ¹× µ¶¼º½ÃÇ衯 ¿Ï·á, ÀÓ»ó½ÃÇè ...
Çѱ¹ÀüÅëÀÇÇп¬ 'µ¿ÃæÇÏÃÊ' Ȱ¿ë ¿îµ¿´É·Â °³¼± ¿ø... 2016
8.11
Çѱ¹ÀüÅëÀÇÇבּ¸¼Ò°¡ '±¹³»»ê ¹ö¼¸(µ¿ÃæÇÏÃÊ) »ê¾÷È­ ¿øÃµ±â¼úÀ» Ȱ¿ëÇÑ À¶º¹ÇÕ ½ºÅ¸Á¦Ç° °³¹ß»ç¾÷'À¸·Î ...
About
Overview
Mission & Values
History
Manufacturing Facilities
Certification
IPRs
R&D Strategy
Portfolio
Valuation
Development Capability
Development Strategy
R&D Center
Research& Pipeline
Core Competence
Pipeline
ATC
CNS
Male Infertility
Allergic rhinitis
Partners
Collaboration Strategy
Global Alliance
Communication
Notice
News& Events
Financial
Investors
Contact us
Map